Levetiracetam Grindex oral solution 100 mg/ml. 300 ml. vial №1

Description

Levetiracetam oral Storage:

active substance: levetiracetam;

1 ml of solution contains 100 mg of levetiracetam;

Excipients: sodium citrate, anhydrous citric acid, methyl parahydroxybenzoate (E 218), glycerin, potassium acesulfame, maltitol liquid, raspberry sweetener, purified water.

Levetiracetam oral Dosage form. The solution is oral.

Main physical and chemical properties: colorless or slightly yellowish transparent liquid.

Pharmacotherapeutic group. Antiepileptic drugs. Levetiracetam.

Code ATX N03A X14.

Levetiracetam oral Pharmacological properties.

Pharmacodynamics.

Levetiracetam is a derivative of pyrrolidone (S-enantiomer of alpha-ethyl-2-oxo-1-pyrrolidine-acetamide), chemically different from known antiepileptic drugs.

The mechanism of action of levetiracetam is insufficiently studied, but it is established that it differs from the mechanism of action of known antiepileptic drugs. Based on in vitro and in vivo studies, it is assumed that levetiracetam does not alter the basic characteristics of the nerve cell and normal neurotransmission. In vitro studies have shown that levetiracetam affects intraneuronal Ca2 + levels by partially suppressing current through N-type Ca2 + channels and reducing Ca2 + release from intraneuronal depots. It also partially offsets the inhibition of GABA and glycine-regulated current due to zinc and beta-carbolines. In addition, in vitro studies, levetiracetam has been associated with specific areas in rodent brain tissue. The binding site is the protein of synaptic vesicles 2A, which is involved in the fusion of vesicles and the release of neurotransmitters. The affinity of levetiracetam and the corresponding analogues with the protein of synaptic vesicles 2A correlated with the strength of their anticonvulsant action in models of audiogenic epilepsy in mice. These results suggest that the interaction between levetiracetam and synaptic vesicle protein 2A may partly explain the mechanism of antiepileptic action of the drug.

Levetiracetam provides protection against seizures in a wide range of models of partial and primary generalized seizures in animals without causing a seizure effect. The major metabolite is inactive.

The activity of the drug was confirmed in relation to both focal and generalized epileptic seizures (epileptiform manifestations / photoparoxysmal reaction).

Levetiracetam oral Indication.

Monotherapy (drug of first choice) in:

– partial seizures with or without secondary generalization in adults and adolescents over 16 years of age who have been diagnosed with epilepsy for the first time.

As adjunctive therapy in:

– partial seizures with or without secondary generalization in adults and children from 1 month of age with epilepsy;

– myoclonic seizures in adults and adolescents over 12 years of age with juvenile myoclonic epilepsy;

– primary generalized tonic-clonic seizures in adults and adolescents over 12 years of age with idiopathic generalized epilepsy.

Contraindication.

Hypersensitivity to levetiracetam or other pyrrolidone derivatives, as well as to any components of the drug.